항바이러스제 시장 규모, 점유율, 성장 분석 : 적응증별, 환자 유형별, 제품 유형별, 약물 유형별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Antiviral Drugs Market size was valued at USD 39.33 Billion in 2024 and is poised to grow from USD 40.71 Billion in 2025 to USD 53.6 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The antiviral drugs market is on a significant growth trajectory, spurred by a rising prevalence of viral infections such as HIV/AIDS, hepatitis B and C, and influenza. This demand has prompted pharmaceutical companies to heavily invest in research and development aimed at creating innovative antiviral therapies that offer enhanced efficacy and better patient compliance. New drug targets and advanced therapeutic strategies are broadening treatment options for healthcare professionals. Growing public awareness of viral infections has further increased the urgency for effective diagnosis and treatment, fueling market expansion. Government initiatives and funding aimed at combating viral diseases, along with collaborative efforts between public and private sectors, are promoting drug discovery and accessibility. Overall, investment in antiviral drug development remains strong, driving sustained market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antiviral Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antiviral Drugs Market Segments Analysis

Global Antiviral Drugs Market is segmented by Indication, Patient Type, Products, Drug Type, End User, Distribution Channel and region. Based on Indication, the market is segmented into Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus, Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus, Respiratory Syncytial Virus, Coronavirus Infection and Others. Based on Patient Type, the market is segmented into Child, Adult and Geriatric. Based on Products, the market is segmented into Oral, Topical and Parenteral. Based on Drug Type, the market is segmented into Generic and Branded. Based on End User, the market is segmented into Hospital, Clinics, Home Healthcare, Speciality Centers, Ambulatory Centers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antiviral Drugs Market

The widespread prevalence of HIV/AIDS has significantly increased the demand for antiretroviral treatments, leading to notable growth within the antiviral drugs market. The advent of advanced antiretroviral therapies has transformed the landscape of HIV/AIDS management, resulting in improved health outcomes and enhanced life expectancy for those affected by the virus. This remarkable progress in treatment options has, in turn, stimulated further market expansion, as healthcare providers and patients seek innovative solutions to combat the challenges posed by viral infections. Consequently, the ongoing evolution and accessibility of antiviral medications continue to propel this vital market forward.

Restraints in the Antiviral Drugs Market

The antiviral drugs market faces notable challenges due to the rigorous and lengthy regulatory approval processes involved. Manufacturers must navigate stringent safety, efficacy, and quality standards, which may result in significant delays before new drugs can enter the market. These strict regulations present obstacles for companies, often affecting the timely introduction of effective antiviral treatments to patients. While adherence to these regulatory frameworks is essential, it can extend the timelines associated with drug development and approval, ultimately impacting the overall availability of crucial antiviral therapies when they are most needed.

Market Trends of the Antiviral Drugs Market

The antiviral drugs market is experiencing a significant shift towards the development of broad-spectrum antiviral medications, which possess the capability to target and inhibit a wide range of viruses regardless of strain variations. This emerging trend is largely motivated by the rising incidence of viral infections and the challenges inherent in creating specific treatments for individual viruses. Broad-spectrum antivirals are seen as cost-effective solutions that enable quicker responses to outbreaks and enhance patient outcomes by offering comprehensive coverage against various pathogens. This market evolution is further fueled by innovations in drug discovery, including novel research methodologies that leverage viral host factor targeting and versatile antiviral mechanisms.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Antiviral Drugs Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Influenza
• Human Immunodeficiency Virus (HIV)
• Hepatitis C Virus
• Herpes Simplex Virus
• Human Cytomegalovirus (HCMV)
• Varicella-Zoster Virus (VZV)
• Hepatitis B Virus
• Respiratory Syncytial Virus
• Coronavirus Infection
• Others

Global Antiviral Drugs Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Child
• Adult
• Geriatric

Global Antiviral Drugs Market Size by Products & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Parenteral

Global Antiviral Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Generic
• Branded

Global Antiviral Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital
• Clinics
• Home Healthcare
• Speciality Centers
• Ambulatory Centers
• Others

Global Antiviral Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Antiviral Drugs Market Size & CAGR (2026-2033)

• North America (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck& C.O., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Meyrs Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N. V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck MRK (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reddy Laboratories Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altesa Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations